Skip to NavigationSkip to content

News

0
Eisai’s Kisplyx (lenvatinib) and Exelisis’s Cabometyx (cabozantinib) are indicated for adult patients with advanced renal cell carcinoma
0
The announcement was made as part of the company’s Q2 results
0
The company had submitted a new drug application for latanoprostene bunod ophthalmic solution
0
Bezlotouxmab is an investigational agent for the prevention of Clostrodium difficile infection recurrence

Features

Here’s a quick look at some of the biggest movers of the week: